Micafungin: A new echinocandin antifungal

Formulary

Volumn 38, Issue 6, 2003, Pages 354-367

  Pawlitz, Dana ^a   Young, Mark ^a   Klepser, Michael ^b  

^a Ferris Stt Univ Coll of Pharmacy   (United States)

^b BORGESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BILIRUBIN; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; MICAFUNGIN; PROTEINASE INHIBITOR; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

ADULT; AGED; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLUS; CANDIDA; CANDIDIASIS; CELL WALL; CHILD; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; ESOPHAGUS DISEASE; FUNGICIDAL ACTIVITY; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION TEST; NAUSEA; NONHUMAN; REVIEW; SYSTEMIC MYCOSIS; VOMITING;

EID: 0038746935     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
2. Thomas AH. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother 1986;17:269-279.
3. Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993;37:1962-1965.
4. Iwamoto T, Sakamoto N, Yamashita M, et al. FR901379, A novel antifungal antibiotic. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993; New Orleans, La. Abstract 371.
5. Kilby JM, Dismukes WE. Antifungal Drugs. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia, Penn: WB Saunders Company; 1998:350-359.
6. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001;10:269-280.
7. Hearn VM. Structure and function of the fungal cell wall. Fungal Disease: Biology, Immunology, and Diagnosis. New York, NY: Marcel Dekker, Inc; 1997:27-60.
8. Denning DW. Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611-614.
9. Nishiyama Y, Uchida K, Yamaguchi H. A morphological study of the antifungal action of FK463, a novel echinocandin-like lipopeptide. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999; San Francisco, Calif. Abstract 156.
10. Suzuki S, Terakawa M, Yokobayashi F, Fujiwara F, Hata T. Pharmacokinetics of FK463, a novel water-soluble echinocandin-like lipopeptide, in animals. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998; San Diego, Calif. Abstract F-144.
11. Azuma J, Yamamoto I, Ogura M, et al. Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers. 38th Interscience Conterence on Antimicrobial Agents and Chemotherapy; 1998; San Diego, Calif. Abstract F-146.
12. Groll AH, Gullick BM, Petraitiene R, et al. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 2001;45:596-600.
13. Mukai T, Ohkuma T, Nakahara K, Takaya T, Uematsu T, Azuma J. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, III. Abstract A-30.
14. Seibel N, Schwartz C, Arrieta A, et al. A phase I study to determine the safety and pharmacokinetics (PK) of FK463 (echinocandin) in febrile neutropenic pediatric patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada. Abstract 18.
15. Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999; San Francisco, Calif. Abstract 1648.
16. Navarro E. Cancidas for invasive aspergillosis: background document. 2001. www.fda.gov/ohrms/dockets/ac/01/briefing/3676B1.htm. Accessed February 12, 2003.
17. Townsend R, Bekersky I, Buell DN, Seibel N. Pharmacokinetic (PK) evaluation of echinocandin FK463 in pediatric and adult patients. 11th Focus on Fungal Infections; 2001; Washington, DC. Abstract 24.
18. Townsend R, Herbert M, Dessimoz M, Wisemandle W, Bekersky I. Pharmacokinetics of micafungin, an echinocandin antifungal, in subjects with moderate hepatic dysfunction. 31st American College of Clinical Pharmacology; 2002; San Francisco, Calif. Abstract 16.
19. Townsend R, Herbert M, Dessimoz M, Wisemandle W, Bekersky I. Pharmacokinetics of micafungin, an echinocandin antifungal, in subjects with severe renal dysfunction. 31st American College of Clinical Pharmacology; 2002; San Francisco, Calif. Abstract 17.
20. Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 2002;48:78-81.
21. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57-62.
22. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000;46:485-487.
23. Laverdiere M, Restieri C, Habel F. In vitro activity of newer antifungal agents against invasive yeast isolates from cancer patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada. Abstract 921.
24. Borg-von Zepelin M, Zaschke K, Monod M, Mueller FC. Influence of micafungin and itraconazole on blocking Candida adherence to epithelial cells. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, Calif. Abstract M-1510.
25. Setevens DA. Susceptibility to micafungin of isolates from clinical trials. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, Calif. Abstract M-1520.
26. Petrairis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002;46:1857-1869.
27. Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000;44:614-618.
28. Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T, Kohno S. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice. Antimicrob Agents Chemother 2000;44:1728-1730.
29. Warn PA, Sharp A, Morrissey G, Denning D. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, Calif. Abstract M-187.
30. Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000;44:619-21.
31. Ito M, Nozu R, Kuramochi T, et al. Prophylactic effect of FK463, a novel antifungal lypopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000;44:2259-2262.
32. Pettengell K, Mynhardt J, Kluyts T, Simjee A, Baraldi E. A multicenter study of the echinocandin antifungal FK463 for the treatment of esophageal candidiasis in HIV positive patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada. Abstract 1104.
33. Suleiman J, Della Negra M, Llanos-Cuentas A, Ticona E, Rex JH, Buell DN. Open label study of micafungin in the treatment of esophageal candidiasis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, Calif. Abstract M-892.
34. Kohno S, Masaoka T, Yamaguchi H. A multicenter open-label clinical study of FK463 in patients with deep mycosis in Japan. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, III. Abstract J-834.
35. Kontoyiannis DP, Buell DN, Frisbee-Hume S, Reddy BT, Rolston KVI. Initial experience with FK463 for the treatment of candidemia in cancer patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, III. Abstract J-1629.
36. Tawara S, Nakai T, Matsumoto K, Ozaki T, Ikeda F, Mutoh S. Effect of micafungin and caspofungin on histamine release, blood pressure and heart rate in rats. 12th Focus on Fungal Infections; 2002; Phoenix, Ariz. Abstract 29.
37. Powles R, Sirohi B, Chopra R, Russel N, Prentice HG. Assessment of maximum tolerated dose of FK463 in cancer patients undergoing haematopoetic stem cell transplantation. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, III. Abstract J-676.
38. Townsend R, Herbert M, Wisemandle W, Bekersky I. Concomitant pharmacokinetics of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers. 31st American College of Clinical Pharmacology; 2002; San Francisco, Calif. Abstract 18.
39. Townsend R, Herbert M, Wisemandle W, Bekersky I. Concomitant pharmacokinetics of cyclosporine and micafungin in healthy adult volunteers. 31st American College of Clinical Pharmacology; 2002; San Francisco, Calif. Abstract 15.